BCL2 and acute myeloid leukemia: Cell viability was determined in AML cell lines treated with increasing dosages of single compounds, as well as in combination treatments using the IRAK4 inhibitor CA4948 and a variety of targeted therapies, including the BCL2 inhibitor venetoclax, the MCL1 inhibitor S63845, and the HSP90 inhibitor PU-H71.